定义致癌 KRAS 之旅的第一部分。

Defining the First Part of the Oncogenic KRAS Journey.

机构信息

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA.

出版信息

Cell Stem Cell. 2020 Oct 1;27(4):499-500. doi: 10.1016/j.stem.2020.09.009.

DOI:10.1016/j.stem.2020.09.009

PMID:33007229

Abstract

Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in ∼30% of all human cancers. In this issue of Cell Stem Cell,Dost et al. (2020) combine the power of analyzing organoid cultures, patient samples, and mouse models with scRNA-seq to elucidate early events occurring with oncogenic KRAS activation.

摘要

四十年前，KRAS 作为原癌基因被发现，其突变存在于所有人类癌症的约 30%中。在本期的《Cell Stem Cell》杂志上，Dost 等人（2020）结合了分析类器官培养物、患者样本和小鼠模型以及 scRNA-seq 的能力，阐明了致癌性 KRAS 激活时发生的早期事件。